查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1629276

肺動脈高壓 (PAH) 治療市場，按藥物類別、給藥途徑、配銷通路、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Pulmonary Arterial Hypertension (PAH) Treatment Market, By Drug Class, By Route of Administration, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 311 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年肺動脈高壓（PAH）治療市值為79.8043億美元，2024年至2032年複合年成長率為5.90%。

肺動脈高壓（PAH）治療市場-市場動態

肺動脈高壓（PAH）盛行率的增加預計將推動市場的成長

隨著全球人口老化，肺動脈高壓（PAH）的盛行率預計將會增加，特別是在更容易出現慢性健康問題的老年人中。隨後患有 PAH 的慢性病患者數量不斷增加，可能需要採取綜合管理方法，從而增加對各種治療替代方案的需求。 PAH 被歸類為一種罕見疾病，盛行率估計為每百萬人 10 至 52 例。根據歐洲呼吸學會的說法，PAH（1型肺動脈高壓）根據潛在的疾病機制進一步分類。儘管如此，增加對臨床研究的投資可能會促進新療法的出現，從而拓寬市場。相反，醫療保健專業人員的意識有限可能會阻礙市場擴張。

肺動脈高壓 (PAH) 治療市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 5.90% 左右的複合年成長率成長

根據藥物類別細分，預計內皮素受體拮抗劑 (ERA) 將在 2023 年顯示最大的市場佔有率

根據給藥途徑細分，口服藥物是 2023 年領先的藥物類別

根據配銷通路細分，醫院藥房是 2023 年領先的藥品類別

按地區分類，北美是 2023 年的主要收入來源

肺動脈高壓（PAH）治療市場-細分分析：

全球肺動脈高壓（PAH）治療市場根據藥物類別、給藥途徑、配銷通路和地區進行細分。

根據藥物類別，市場分為四個部分：前列環素和前列環素類似物、磷酸二酯酶5 (PDE 5) 抑制劑、內皮素受體拮抗劑(ERA) 和可溶性鳥苷酸環化酶(SGC) 促效劑。其中，內皮素受體拮抗劑（ERA）在市場上佔據主導地位。 ERA 在肺動脈高壓 (PAH) 的治療中至關重要，因為它們抑制內皮素的作用，內皮素是一種血管收縮劑，可導致與 PAH 相關的肺動脈血壓升高。

根據給藥途徑，市場分為三類：口服、靜脈/皮下和吸入。口服品類是市場成長的主要驅動力。口服療法對於肺動脈高壓（PAH）尤其重要，因為它們給藥方便，通常適合長期使用，並增強患者的依從性，特別是對於需要持續治療這種慢性疾病的個體。

根據配銷通路，市場分為三類：醫院藥房、零售藥房和線上藥房。醫院藥房在市場上佔據主導地位。它們是 PAH 藥物的主要配銷通路，特別是需要密切醫療監督的治療，包括靜脈注射和注射治療。

肺動脈高壓 (PAH) 治療市場 - 地理洞察

北美地區憑藉其先進的醫療基礎設施和專業醫療設施引領市場。北美的醫療保健提供者受益於最先進的診斷和治療技術，這些技術增強了疾病管理並帶來更好的患者治療結果。根據美國醫學會統計，2022年美國醫療支出成長4.1%，達到4.5兆美元，即人均13,493美元。這一成長率與疫情前的數據一致，2019 年也為 4.1%。隨著意識和診斷能力的不斷提高，多環芳烴治療市場預計將在多個地區持續成長。

肺動脈高壓（PAH）治療市場-競爭格局：

肺動脈高壓（PAH）治療市場的特點是競爭激烈，許多製藥公司致力於為這種慢性且可能致命的疾病創造突破性的療法。這些公司的普遍策略是持續投資臨床試驗，旨在評估新療法、組合和劑型，因為這些進步可能會重新定義 PAH 的護理標準。此外，許多組織正在擴大其在新興市場的業務，這些市場對 PAH 的認知和診斷不斷增強，以獲得競爭優勢。

最新進展：

在獲得美國食品藥物管理局的初步批准後，一種名為Yutrepia 的新型曲前列環素製劑可能很快可供患有肺動脈高壓(PAH) 和與間質性肺部疾病(PH-ILD) 相關的肺動脈高壓的患者使用。

輝瑞宣布，一項旨在評估靜脈注射(IV) 西地那非聯合吸入一氧化氮(iNO) 治療新生兒持續性肺動脈高壓(PPHN) 的有效性和安全性的3 期臨床試驗並未實現其主要療效目標。

目錄

第 1 章：肺動脈高壓 (PAH) 治療市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按藥物類別分類的肺動脈高壓 (PAH) 治療市場片段
    • 按給藥途徑分類的肺動脈高壓 (PAH) 治療市場摘要
    • 按配銷通路分類的肺動脈高壓 (PAH) 治療市場片段
    • 肺動脈高壓 (PAH) 治療市場片段（按國家/地區）
    • 按地區分類的肺動脈高壓 (PAH) 治療市場片段
  • 競爭洞察

第 3 章：肺動脈高壓 (PAH) 治療主要市場趨勢

  • 肺動脈高壓（PAH）治療市場促進因素
    • 市場促進因素的影響分析
  • 肺動脈高壓（PAH）治療市場限制
    • 市場限制影響分析
  • 肺動脈高壓（PAH）治療市場機會
  • 肺動脈高壓（PAH）治療市場未來趨勢

第 4 章：肺動脈高壓 (PAH) 治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：肺動脈高壓 (PAH) 治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：肺動脈高壓 (PAH) 治療市場格局

  • 2023 年肺動脈高壓 (PAH) 治療市場佔有率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：肺動脈高壓 (PAH) 治療市場 - 按藥物類別

  • 概述
    • 按藥物類別分類的細分市場佔有率分析
    • 前列環素和前列環素類似物
    • 磷酸二酯酶 5 (PDE 5) 抑制劑
    • 內皮素受體拮抗劑 (ERA)
    • 可溶性鳥苷酸環化酶 (SGC) 促效劑

第 8 章：肺動脈高壓 (PAH) 治療市場 - 按給藥途徑

  • 概述
    • 按給藥途徑分類的細分市場佔有率分析
    • 口服
    • 靜脈注射/皮下注射
    • 吸入式

第 9 章：肺動脈高壓 (PAH) 治療市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第 10 章：肺動脈高壓 (PAH) 治療市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美肺動脈高壓 (PAH) 治療主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按藥物類別）
    • 北美市場規模與預測（按管理途徑）
    • 北美市場規模和預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲肺動脈高壓 (PAH) 治療主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按藥物類別）
    • 歐洲市場規模與預測（按管理途徑）
    • 歐洲市場規模和預測（按配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區肺動脈高壓 (PAH) 治療主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模和預測（按藥物類別）
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模和預測（按配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲肺動脈高壓 (PAH) 治療主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按藥物類別）
    • 拉丁美洲市場規模與預測（按管理途徑）
    • 拉丁美洲市場規模和預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲肺動脈高壓 (PAH) 治療主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按藥物類別）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模及預測（按配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - 肺動脈高壓 (PAH) 治療產業

  • 競爭儀表板
  • 公司簡介
    • United Therapeutics Ltd.
    • Bayer AG
    • Actelion Ltd.
    • Pfizer, Inc.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Teva Pharmaceuticals Inc.
    • Eli Lilly and Company
    • Steady Med Ltd.
    • Johnson & Johnson Services, Inc.
    • Others

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4444

REPORT HIGHLIGHT

The Pulmonary Arterial Hypertension (PAH) Treatment Market was valued at USD 7,980.43 million in 2023 and expanded at a CAGR of 5.90% from 2024 to 2032.

Pulmonary Arterial Hypertension (PAH) is an uncommon yet significant medical condition marked by increased blood pressure within the pulmonary arteries, potentially resulting in heart failure and various other complications. The primary objective of PAH treatment is to alleviate symptoms, enhance the quality of life, and decelerate the progression of the disease. Consistent monitoring of symptoms, functional capacity, and the effectiveness of treatment are essential for the successful management of PAH. Typically, a multidisciplinary team of healthcare professionals, including cardiologists, pulmonologists, and pulmonary medicine specialists, collaborates to provide thorough management of the condition.

Pulmonary Arterial Hypertension (PAH) Treatment Market- Market Dynamics

Increasing Prevalence of Pulmonary Arterial Hypertension (PAH) is anticipated to drive the growth of the market

As the global demographic shifts towards an older population, the prevalence of pulmonary arterial hypertension (PAH) is anticipated to increase, especially among elderly individuals who are more vulnerable to chronic health issues. The rising number of patients with chronic diseases who subsequently develop PAH will likely necessitate comprehensive management approaches, thereby heightening the demand for various treatment alternatives. PAH is classified as a rare condition, with prevalence estimates ranging from 10 to 52 cases per million individuals. According to the European Respiratory Society, PAH (Group 1 pulmonary hypertension) is further divided based on the underlying disease mechanisms. Nevertheless, enhanced investment in clinical research may facilitate the emergence of novel therapies, thereby broadening the market. Conversely, limited awareness among healthcare professionals could hinder market expansion.

Pulmonary Arterial Hypertension (PAH) Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.90% over the forecast period (2024-2032)

Based on Drug Class segmentation, Endothelin Receptor Antagonists (ERA) was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Oral was the leading Drug Class in 2023

Based on Distribution Channel segmentation, Hospital Pharmacies was the leading Drug Class in 2023

Based on region, North America was the leading revenue generator in 2023

Pulmonary Arterial Hypertension (PAH) Treatment Market- Segmentation Analysis:

The Global Pulmonary Arterial Hypertension (PAH) Treatment Market is segmented based on Drug Class, Route of Administration, Distribution Channel, and Region.

The market is categorized into four segments according to Drug Class: Prostacyclin and Prostacyclin Analogs, Phosphodiesterase 5 (PDE 5) Inhibitors, Endothelin Receptor Antagonists (ERA), and Soluble Guanylate Cyclase (SGC) Stimulators. Among these, Endothelin Receptor Antagonists (ERAs) holds a dominant position in the market. ERAs are essential in the treatment of pulmonary arterial hypertension (PAH) as they inhibit the effects of endothelin, a vasoconstrictor that contributes to elevated blood pressure in the pulmonary arteries associated with PAH.

The market is segmented into three categories according to the Route of Administration: Oral, Intravenous/Subcutaneous, and Inhalational. The Oral category is the primary driver of market growth. Oral therapies are especially significant for pulmonary arterial hypertension (PAH) as they provide convenience in administration, are generally appropriate for long-term use, and enhance patient adherence, particularly for individuals needing continuous management of this chronic illness.

The market is segmented into three categories according to the Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies hold a dominant position in the market. They function as the principal distribution channel for PAH medications, particularly for therapies that necessitate close medical oversight, including intravenous and injectable treatments.

Pulmonary Arterial Hypertension (PAH) Treatment Market- Geographical Insights

The North American region leads the market, attributed to its advanced healthcare infrastructure and specialized medical facilities. Healthcare providers in North America benefit from access to state-of-the-art diagnostic and therapeutic technologies, which enhance disease management and lead to better patient outcomes. According to the American Medical Association, health expenditures in the United States rose by 4.1% in 2022, reaching USD 4.5 trillion, or USD 13,493 per capita. This growth rate aligns with pre-pandemic figures, which also stood at 4.1% in 2019. Meanwhile, the Asia-Pacific region offers significant growth potential, driven by a strong focus on research and development. As awareness and diagnostic capabilities continue to advance, the PAH treatment market is expected to experience sustained growth across multiple regions.

Pulmonary Arterial Hypertension (PAH) Treatment Market- Competitive Landscape:

The market for Pulmonary Arterial Hypertension (PAH) treatment is characterized by intense competition, with a multitude of pharmaceutical firms dedicated to creating groundbreaking therapies for this chronic and potentially fatal condition. A prevalent strategy among these companies is the ongoing investment in clinical trials aimed at evaluating new therapies, combinations, and dosage forms, as such advancements may redefine the standards of care for PAH. Additionally, many organizations are broadening their operations in emerging markets, where there is an increasing awareness and diagnosis of PAH, to gain a competitive advantage.

Recent Developments:

A novel formulation of treprostinil, known as Yutrepia, may soon be accessible to individuals suffering from pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD), following the tentative approval granted by the Food and Drug Administration (FDA) earlier this month.

Pfizer Inc. has announced that a Phase 3 clinical trial aimed at evaluating the efficacy and safety of intravenous (IV) sildenafil in conjunction with inhaled nitric oxide (iNO) for treating newborns with Persistent Pulmonary Hypertension (PPHN) did not achieve its primary efficacy objective.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • United Therapeutics Ltd.
  • Bayer AG
  • Actelion Ltd.
  • Pfizer, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Steady Med Ltd.
  • Johnson & Johnson Services, Inc.
  • Others

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Prostacyclin and Prostacyclin Analogs
  • Phosphodiesterase 5 (PDE 5) Inhibitors
  • Endothelin Receptor Antagonists (ERA)
  • Soluble Guanylate Cyclase (SGC) Stimulator

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous/ subcutaneous
  • Inhalational

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Pulmonary Arterial Hypertension (PAH) Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Drug Class
    • 2.1.2. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Route of Administration
    • 2.1.3. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Distribution Channel
    • 2.1.4. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Country
    • 2.1.5. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Pulmonary Arterial Hypertension (PAH) Treatment Key Market Trends

  • 3.1. Pulmonary Arterial Hypertension (PAH) Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Pulmonary Arterial Hypertension (PAH) Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Pulmonary Arterial Hypertension (PAH) Treatment Market Opportunities
  • 3.4. Pulmonary Arterial Hypertension (PAH) Treatment Market Future Trends

4. Pulmonary Arterial Hypertension (PAH) Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Pulmonary Arterial Hypertension (PAH) Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Pulmonary Arterial Hypertension (PAH) Treatment Market Landscape

  • 6.1. Pulmonary Arterial Hypertension (PAH) Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Pulmonary Arterial Hypertension (PAH) Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. Prostacyclin and Prostacyclin Analogs
    • 7.1.3. Phosphodiesterase 5 (PDE 5) Inhibitors
    • 7.1.4. Endothelin Receptor Antagonists (ERA)
    • 7.1.5. Soluble Guanylate Cyclase (SGC) Stimulator

8. Pulmonary Arterial Hypertension (PAH) Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Intravenous/ subcutaneous
    • 8.1.4. Inhalational

9. Pulmonary Arterial Hypertension (PAH) Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Pulmonary Arterial Hypertension (PAH) Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Pulmonary Arterial Hypertension (PAH) Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. United Therapeutics Ltd.
    • 11.2.2. Bayer AG
    • 11.2.3. Actelion Ltd.
    • 11.2.4. Pfizer, Inc.
    • 11.2.5. Gilead Sciences, Inc.
    • 11.2.6. GlaxoSmithKline plc
    • 11.2.7. Teva Pharmaceuticals Inc.
    • 11.2.8. Eli Lilly and Company
    • 11.2.9. Steady Med Ltd.
    • 11.2.10. Johnson & Johnson Services, Inc.
    • 11.2.11. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us